Fuse Oncology

AMP, Fuse Oncology Launch FuseRx Radiation Workflow Pilot in Syracuse

Syracuse – – September 29, 2026 -- Fuse Oncology and Associated Medical Professionals of NY (AMP), an affiliate of U.S. Urology Partners, a General Atlantic company, have launched a proof of concept for FuseRx, a clinical workflow platform for radiation oncology, at AMP's Center of Advanced Radiation Excellence in Syracuse.

Prostate cancer volume drives the test case

The American Cancer Society projects about 333,800 new U.S. prostate cancer cases in 2026, making it the most common cancer in American men after skin cancer. Roughly a third of men with localized disease receive radiation as primary treatment, a pathway that typically starts with a urologist diagnosis before crossing into separate oncology systems.

Fuse Oncology to Showcase GE HealthCare iRT-S!GNAL Workflow at ASTRO 2026

Boone, N.C. – September 27, 2026 -- Fuse Oncology plans to demonstrate a potential integration linking GE HealthCare's Intelligent Radiation Therapy (iRT) software to its S!GNAL charge capture platform at the ASTRO 2026 Annual Meeting, running September 27-29 in Boston at booth 2533.

Concept links radiation therapy workflow software directly to charge review

The showcased workflow would allow iRT to launch S!GNAL using existing patient information, giving radiation oncology teams a direct path from treatment coordination to targeted charge review without re-entering data across systems. The capability is described as planned for a future iRT release and is currently in development and evaluation, with no confirmed commercial availability date.